Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 31, 2003

Primary Completion Date

December 31, 2009

Study Completion Date

July 31, 2011

Conditions
Ischemic Stroke
Interventions
DRUG

Aspirin

A single 81 mg aspirin tablet orally (or rectal suppository equivalent dose) given as soon as possible after start of standard iv tPA and consent.

DRUG

tinzaparin sodium

A single weight-based dose of 80 anti-Xa International Units/kilogram (IU/kg)administered by subcutaneous (SQ) injection.

DRUG

eptifibatide

Eptifibatide administered iv according to dose escalation group. The five dosing groups for eptifibatide are 0, 45 µg/kg bolus, 90 µg/kg bolus, 90 µg/kg bolus plus 0.25 µg/kg/min infusion for 24 hours, and 90 µg/kg bolus plus 0.5 µg/kg/min infusion for 24 hours.

Trial Locations (3)

20010

Washington Hospital Center, Washington D.C.

20892

National Institutes of Health Clinical Center, Bethesda

Suburban Hospital, Bethesda

All Listed Sponsors
lead

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

NCT00061373 - Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST) | Biotech Hunter | Biotech Hunter